% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kobold:305555,
      author       = {S. Kobold$^*$ and R. Müller},
      title        = {{C}urrent progress and latest therapeutic options in
                      immuno-oncology.[{A}ktuelle {F}ortschritte und neue
                      {T}herapieoptionen in der {I}mmunonkologie.]},
      journal      = {Deutsche medizinische Wochenschrift},
      volume       = {150},
      number       = {22},
      issn         = {0012-0472},
      address      = {Stuttgart},
      publisher    = {Thieme},
      reportid     = {DKFZ-2025-02225},
      pages        = {1335 - 1340},
      year         = {2025},
      abstract     = {Recently approved immunotherapeutic agents in Europe mostly
                      consist of monoclonal antibody-based products. For solid
                      cancers, these comprise the antibody-drug-conjugate
                      Mirvetuximab Soravtansine for platinum-resistant ovarian
                      cancer, the monoclonal antibody Zolbetuximab for
                      Claudin-18.2 positive gastric adenocarcinoma and the
                      checkpoint inhibitor Tislelizumab for esophageal squamous
                      cell carcinoma. For the treatment of relapsed or refractory
                      hematologic B cell malignancies, the use of bispecific T
                      cell engaging antibodies like the BCMA-CD3 targeting
                      Teclistamab and CD20-CD3 targeting Glofitamab were approved
                      by the EMA recently.Combinatorial approaches of conventional
                      chemotherapy and checkpoint inhibitors for the treatment of
                      cholangiocarcinoma, urothelial carcinoma and endometrial
                      carcinoma received recent approval.A CD38 antibody-based
                      bridging therapy for the treatment of newly diagnosed
                      multiple myeloma and the Glofitamab-based approach in
                      combination with Gemcitabine and Oxaliplatin for relapsed
                      DLBCL are the latest additions for hematologic malignancies
                      after promising clinical trials.The first T cell products
                      for the treatment of solid cancers using either
                      tumor-infiltrating lymphocytes or TCR-engineered peripheral
                      blood T cells were approved by the FDA in 2024, for the
                      treatment of advanced melanoma (Lifileucel) and synovial
                      sarcoma (Afamitresgene autoleucel). To further expand the
                      success of T cell products to solid tumors, promising
                      preclinical studies suggest solutions to main obstacles,
                      such as modular CAR T cells, targeting of two antigens
                      simultaneously or generation of cytokine-secreting 4th
                      generation CAR T cells.},
      subtyp        = {Review Article},
      keywords     = {Humans / Neoplasms: therapy / Neoplasms: immunology /
                      Immunotherapy: methods / Immunotherapy: trends / Antibodies,
                      Monoclonal: therapeutic use / Medical Oncology: trends /
                      Antibodies, Monoclonal (NLM Chemicals)},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41151612},
      doi          = {10.1055/a-2502-1305},
      url          = {https://inrepo02.dkfz.de/record/305555},
}